Singapore: ASLAN Pharma to list on Taipei Exchange, targets $40m IPO

Singapore: ASLAN Pharma to list on Taipei Exchange, targets $40m IPO

Photo: Pixabay

ASLAN Pharmaceuticals, a Singapore-based biotechnology company focused on the development of immunotherapies for Asia prevalent tumour types, intends to launch an initial public offering (IPO) on the Taipei Exchange in mid-May and expects to start trading in early June 2017.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter